Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oramed Pharmaceuticals Inc. (ORMP)
USD4.00
+0.00 (+0.13%)
US NASDAQ Healthcare Biotechnology
Address
1185 Avenue of the Americas 10036
New York City, NY, US
New York City, NY, US
CEO
Nadav Kidron
Website
oramed.com
IPO
2007-05-01
CIK 1176309 ISIN US68403P2039
Also trades on
NASDAQ Capital Market · ORMP (USD)
Tel Aviv Stock Exchange · ORMP.TA (ILA)
Description
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.00
+0.00 (+0.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
276.9K
Beta
1.24
Float Shares
31.61M
Free Float %
77.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.25% | -0.75% | +2.32% | +16.08% | +39.30% | +39.30% | +66.81% | -1.73% | -65.98% | -54.47% | -66.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
4.00
DCF (Unlevered)
1.18
-70.4%
DCF (Levered)
0.98
-75.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.07
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
A+
Overall Score
5 / 5
High
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%— Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+419.2% ★ Q1'26: +578.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+3,105.5%
-
EBIT margin Biotechnology: +0.0%+3,766.2% ★
-
ROIC Biotechnology: -16.1%+85.7% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.9% Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.01× ★
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
641.0K
est: 468.0K (+37.0%)
|
2.46M
est: 2.46M (+0.0%)
|
2.45M
est: 2.44M (+0.4%)
|
2.70M
est: 2.70M (+0.2%)
|
2.71M
est: 4.37M (-38.0%)
|
2.70M
est: 2.92M (-7.5%)
|
2.70M
est: 2.77M (-2.3%)
|
1.34M
est: 674.0K (+98.8%)
|
—
est: 750.0K (-100.0%)
|
2.00M
est: 2.00M (+0.0%)
|
1.25M
1.25M – 1.25M
-37.6% YoY
|
778.6K
778.6K – 778.6K
-37.6% YoY
|
| EBITDA |
-9.99M
est: -93.6K (-10,572.1%)
|
-10.76M
est: -491.0K (-2,090.6%)
|
-13.49M
est: -487.9K (-2,665.1%)
|
-14.17M
est: -539.4K (-2,527.6%)
|
-11.31M
est: -874.1K (-1,194.2%)
|
-25.04M
est: -584.2K (-4,186.3%)
|
-36.98M
est: -553.5K (-6,580.7%)
|
7.32M
est: -134.8K (+5,531.0%)
|
-14.87M
est: 150.0K (-10,016.1%)
|
75.45M
est: 400.0K (+18,761.3%)
|
249.6K
249.6K – 249.6K
-37.6% YoY
|
155.7K
155.7K – 155.7K
-37.6% YoY
|
| EBIT |
-10.01M
est: -93.6K (-10,594.6%)
|
-10.77M
est: -491.0K (-2,093.7%)
|
-13.53M
est: -487.9K (-2,672.5%)
|
—
est: -539.4K (+100.0%)
|
—
est: -874.1K (+100.0%)
|
—
est: -584.2K (+100.0%)
|
-40.60M
est: -553.5K (-7,235.1%)
|
7.13M
est: -134.8K (+5,385.6%)
|
-15.07M
est: 150.0K (-10,144.7%)
|
75.32M
est: 400.0K (+18,731.0%)
|
249.6K
249.6K – 249.6K
-37.6% YoY
|
155.7K
155.7K – 155.7K
-37.6% YoY
|
| Net Income |
-10.96M
est: -26.54M (+58.7%)
|
-10.48M
est: -31.85M (+67.1%)
|
-12.73M
est: -38.79M (+67.2%)
|
-14.36M
est: -36.75M (+60.9%)
|
-11.51M
est: -32.53M (+64.6%)
|
-22.24M
est: -32.83M (+32.3%)
|
-37.76M
est: -38.22M (+1.2%)
|
5.53M
est: 21.75M (-74.6%)
|
-19.10M
est: -24.16M (+20.9%)
|
64.05M
est: -14.42M (+544.1%)
|
-53.45M
-53.45M – -53.45M
-270.6% YoY
|
-34.78M
-34.78M – -34.78M
+34.9% YoY
|
| SGA |
2.45M
est: 1.56M (+57.6%)
|
2.76M
est: 8.16M (-66.2%)
|
4.08M
est: 8.11M (-49.7%)
|
3.72M
est: 8.97M (-58.5%)
|
4.23M
est: 14.53M (-70.9%)
|
5.94M
est: 9.71M (-38.9%)
|
15.66M
est: 9.20M (+70.2%)
|
8.14M
est: 2.62M (+210.8%)
|
6.46M
est: 2.91M (+121.6%)
|
8.72M
est: 7.77M (+12.2%)
|
4.85M
4.85M – 4.85M
-37.6% YoY
|
3.02M
3.02M – 3.02M
-37.6% YoY
|
| EPS |
-0.87
est: -0.65 (-33.8%)
|
-0.79
est: -0.78 (-1.3%)
|
-0.86
est: -0.95 (+9.5%)
|
-0.82
est: -0.90 (+8.9%)
|
-0.56
est: -0.80 (+29.7%)
|
-0.78
est: -0.80 (+3.0%)
|
-0.97
est: -0.94 (-3.6%)
|
0.14
est: 0.51 (-72.7%)
|
-0.47
est: -0.24 (-95.8%)
|
1.53
est: -0.34 (+550.0%)
|
-1.26
-1.26 – -1.26
-270.6% YoY
|
-0.82
-0.82 – -0.82
+34.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-27 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-26 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-22 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-14 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-13 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-12 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-11 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-08 | S- | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-07 | S- | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-06 | S- | 5/5 | 3/5 | 5/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-05 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-24 | A+ | 5/5 | 3/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-23 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-22 | A+ | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-21 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.67M
OE per share TTM
-0.30
Owner's Yield
-7.83%
Maintenance CapEx ratio
2.58%
Maint CapEx / Avg PPE
49.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
64
Total invested
45.02M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Franklin Resources, Inc. | 3.57M | 6.50% | 6.48M | — | 6.48M | — | HC, CO | Cayman Islands | 2011-01-19 | ↗ |
| 2 | VANGUARD SPECIALIZED FUNDS - VANGUARD REIT INDEX FUND | 2.78M | 5.01% | — | 960.0K | — | 960.0K | IV | Cayman Islands | 2018-07-03 | ↗ |
| 3 | Nadav Kidron | 2.34M | 5.70% | 2.13M | 218.6K | 2.13M | — | IN | Israel | 2024-03-22 | ↗ |
| 4 | BML Investment Partners, L.P. | 2.05M | 5.00% | — | 2.05M | — | 2.05M | PN | Delaware | 2024-09-16 | ↗ |
| 5 | BARCLAYS GLOBAL INVESTORS, NA. | 1.98M | 2.61% | — | 790.0K | — | 790.0K | BK | Cayman Islands | 2013-12-31 | ↗ |
| 6 | Mark McLean | 1.49M | 11.00% | 1.49M | — | — | — | IN | Canadian | 2005-08-01 | ↗ |
| 7 | David M. Slager | 1.34M | 5.04% | — | 1.34M | — | 1.34M | PN | Delaware | 2021-02-09 | ↗ |
| 8 | Regals Capital Management LP | 1.34M | 5.04% | — | 1.34M | — | 1.34M | IN | Delaware | 2021-02-09 | ↗ |
| 9 | Regals Fund LP | 1.34M | 5.04% | — | 1.34M | — | 1.34M | PN | Delaware | 2021-02-09 | ↗ |
| 10 | Trevor Sali | 1.14M | 11.00% | 1.14M | — | — | — | IN | Canadian | 2005-07-21 | ↗ |
| 11 | Anthony Cheung | 990.0K | 11.00% | 990.0K | — | — | — | IN | Canadian | 2005-08-24 | ↗ |
| 12 | Jeremy Ross | 990.0K | 11.00% | 990.0K | — | — | — | IN | Canadian | 2005-07-20 | ↗ |
| 13 | Altium Capital Growth GP, LLC | 972.0K | 5.61% | — | 972.0K | — | — | PN | Delaware, United States of America | 2018-07-13 | ↗ |
| 14 | Altium Capital Management, LP | 972.0K | 4.99% | — | 972.0K | — | — | IA | United State of America | 2019-02-13 | ↗ |
| 15 | Altium Growth Fund, LP | 972.0K | 4.99% | — | 972.0K | — | — | PN | United States of America | 2019-02-13 | ↗ |
| 16 | Altium Growth GP, LLC | 972.0K | 4.99% | — | 972.0K | — | — | PN | United States of America | 2019-02-13 | ↗ |
| 17 | Armistice Capital Master Fund Ltd. | 856.4K | 4.90% | — | 856.4K | — | 856.4K | CO | Delaware | 2018-07-12 | ↗ |
| 18 | Armistice Capital, LLC | 856.4K | 4.90% | — | 856.4K | — | 856.4K | IA, OO | Delaware | 2018-07-12 | ↗ |
| 19 | Steven Boyd | 856.4K | 4.90% | — | 856.4K | — | 856.4K | HC, IN | Delaware | 2018-07-12 | ↗ |
| 20 | Zeev Bronfeld | 697.2K | 9.60% | 475.2K | 697.2K | 475.2K | — | IN | Israel | 2013-02-05 | ↗ |
| 21 | Leonard Sank | 571.4K | 5.20% | 327.1K | 244.4K | 327.1K | 10.00 | IN | South Africa | 2014-12-15 | ↗ |
| 22 | Miriam Kidron | 469.1K | 6.10% | 469.1K | — | 469.1K | 10.00 | IN | Israel | 2013-02-11 | ↗ |
| 23 | Prudential Financial, Inc. | — | 12.00% | — | 1.38M | — | 1.38M | IA | Delaware | 2014-02-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
64
+7 vs prev Q
New positions
16
Closed positions
9
Increased
35
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BML CAPITAL MANAGEMENT, LLC | 3.17M +— (+0.0%) | 9.03M +665.1K (+8.0%) | 7.59% -0.002 pp | 7.80% +0.147 pp | USD2.37 +20.3% | 12 qtrs — |
| 2 | MURCHINSON LTD. | 1.34M -411.3K (-23.5%) | 3.82M -804.4K (-17.4%) | 3.21% -0.986 pp | 0.61% +0.028 pp | USD2.46 +15.9% | 9 qtrs — |
| 3 | BOOTHBAY FUND MANAGEMENT, LLC | 612.2K -233.2K (-27.6%) | 1.74M -487.2K (-21.8%) | 1.47% -0.559 pp | 0.03% -0.006 pp | USD2.45 +16.3% | 9 qtrs — |
| 4 | MARSHALL WACE, LLP | 259.1K +259.1K (+100.0%) | 738.3K +738.3K (+100.0%) | 0.62% +0.620 pp | 0.00% +0.001 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 5 | RATHBONES GROUP PLC | 233.0K +— (+0.0%) | 664.1K +48.9K (+8.0%) | 0.56% 0.000 pp | 0.00% +0.000 pp | USD2.61 +9.2% | 10 qtrs — |
| 6 | CITADEL ADVISORS LLC | 196.0K +84.3K (+75.5%) | 558.7K +263.8K (+89.4%) | 0.47% +0.202 pp | 0.00% +0.000 pp | USD2.56 +11.3% | 6 qtrs — |
| 7 | DIMENSIONAL FUND ADVISORS LP | 150.5K +3.0K (+2.0%) | 428.8K +39.5K (+10.1%) | 0.36% +0.007 pp | 0.00% +0.000 pp | USD2.43 +17.3% | 10 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 147.5K -1.4K (-0.9%) | 420.4K +27.3K (+6.9%) | 0.35% -0.004 pp | 0.00% +0.000 pp | USD2.47 +15.4% | 12 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | 142.2K -7.4K (-5.0%) | 405.4K +10.3K (+2.6%) | 0.34% -0.018 pp | 0.00% +0.000 pp | USD2.58 +10.5% | 44 qtrs — |
| 10 | WELLS FARGO & COMPANY/MN | 130.6K +500.0 (+0.4%) | 372.2K +28.7K (+8.4%) | 0.31% +0.001 pp | 0.00% +0.000 pp | USD2.74 +4.0% | 44 qtrs — |
| 11 | BLACKROCK, INC. | 90.2K -19.5K (-17.8%) | 257.1K -32.6K (-11.3%) | 0.22% -0.047 pp | 0.00% +0.000 pp | USD2.48 +14.9% | 6 qtrs — |
| 12 | JANE STREET GROUP, LLC | 78.3K +18.6K (+31.2%) | 223.0K +65.5K (+41.6%) | 0.19% +0.045 pp | 0.00% +0.000 pp | USD2.89 -1.4% | 27 qtrs — |
| 13 | SQUAREPOINT OPS LLC | 58.3K +28.4K (+95.1%) | 166.1K +87.2K (+110.6%) | 0.14% +0.068 pp | 0.00% +0.000 pp | USD2.78 +2.5% | 11 qtrs — |
| 14 | HRT FINANCIAL LP | 46.1K +46.1K (+100.0%) | 131.0K +131.0K (+100.0%) | 0.11% +0.110 pp | 0.00% +0.000 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 15 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 43.7K +15.5K (+54.9%) | 124.6K +50.1K (+67.2%) | 0.10% +0.037 pp | 0.00% +0.000 pp | USD2.59 +10.0% | 6 qtrs — |
| 16 | RBF CAPITAL, LLC | 42.9K +— (+0.0%) | 122.4K +9.0K (+8.0%) | 0.10% +0.000 pp | 0.01% +0.000 pp | USD2.14 +33.2% | 4 qtrs — |
| 17 | QUADRATURE CAPITAL LTD | 41.7K +41.7K (+100.0%) | 118.9K +118.9K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.001 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 18 | XTX TOPCO LTD | 38.2K +14.3K (+59.9%) | 108.8K +45.8K (+72.6%) | 0.09% +0.034 pp | 0.00% 0.000 pp | USD2.72 +4.8% | 2 qtrs — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 26.0K -10.8K (-29.4%) | 74.1K -23.2K (-23.8%) | 0.06% -0.026 pp | 0.00% +0.000 pp | USD2.76 +3.3% | 20 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 25.4K +25.4K (+100.0%) | 72.5K +72.5K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.000 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 24.3K +— (+0.0%) | 69.2K +5.1K (+8.0%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD9.72 -70.7% | 27 qtrs — |
| 22 | TWO SIGMA SECURITIES, LLC | 23.1K +23.1K (+100.0%) | 66.0K +66.0K (+100.0%) | 0.06% +0.055 pp | 0.01% +0.009 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 23 | — | 23.0K +23.0K (+100.0%) | 65.6K +65.6K (+100.0%) | 0.06% +0.055 pp | 0.06% +0.064 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 24 | PRELUDE CAPITAL MANAGEMENT, LLC | 21.6K +21.6K (+100.0%) | 61.6K +61.6K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.005 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 25 | PNC FINANCIAL SERVICES GROUP, INC. | 21.2K -2.0K (-8.6%) | 60.4K -828.0 (-1.4%) | 0.05% -0.005 pp | 0.00% +0.000 pp | USD6.14 -53.6% | 43 qtrs — |
| 26 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 18.3K -500.0 (-2.7%) | 56.2K +9.6K (+20.5%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD2.49 +14.5% | 10 qtrs — |
| 27 | AMERICAN CENTURY COMPANIES INC | 19.6K +— (+0.0%) | 55.8K +4.1K (+8.0%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD3.19 -10.7% | 11 qtrs — |
| 28 | MORGAN STANLEY | 17.6K +710.0 (+4.2%) | 50.3K +5.6K (+12.5%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD8.11 -64.9% | 49 qtrs — |
| 29 | JPMORGAN CHASE & CO | 17.3K +17.1K (+10,063.5%) | 49.2K +48.8K (+10,867.0%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD2.85 +0.0% | 2 qtrs — |
| 30 | SAGE CAPITAL MANAGEMENT, LLC | 16.8K +— (+0.0%) | 47.7K +3.5K (+8.0%) | 0.04% +0.000 pp | 0.02% +0.002 pp | USD2.83 +0.7% | 8 qtrs — |
| 31 | LPL FINANCIAL LLC | 13.2K -400.0 (-2.9%) | 37.6K +1.7K (+4.8%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD2.90 -1.7% | 11 qtrs — |
| 32 | ALGERT GLOBAL LLC | 12.1K +12.1K (+100.0%) | 34.0K +34.0K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.001 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 33 | CLOSE ASSET MANAGEMENT LTD | 11.7K +— (+0.0%) | 33.0K +2.0K (+6.5%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD3.85 -26.0% | 37 qtrs — |
| 34 | ALTSHULER SHAHAM LTD | 11.2K +— (+0.0%) | 32.0K +2.4K (+8.0%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD12.03 -76.3% | 13 qtrs — |
| 35 | MARINER, LLC | 11.0K +— (+0.0%) | 31.4K +2.3K (+8.0%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD2.28 +25.0% | 3 qtrs — |
| 36 | GLASS JACOBSON INVESTMENT ADVISORS LLC | 10.5K +— (+0.0%) | 30.0K +2.2K (+8.0%) | 0.03% +0.000 pp | 0.01% +0.001 pp | USD3.58 -20.4% | 11 qtrs — |
| 37 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 9.3K +440.0 (+5.0%) | 26.4K +3.1K (+13.3%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD2.83 +0.7% | 8 qtrs — |
| 38 | BARCLAYS PLC | 6.9K -6.3K (-47.8%) | 19.7K -12.6K (-39.0%) | 0.02% -0.015 pp | 0.00% +0.000 pp | USD9.42 -69.7% | 41 qtrs — |
| 39 | ADVISOR GROUP HOLDINGS, INC. | 4.3K +— (+0.0%) | 12.3K +2.8K (+28.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD7.91 -64.0% | 21 qtrs — |
| 40 | N.E.W. ADVISORY SERVICES LLC | 3.2K +3.2K (+100.0%) | 9.1K +9.1K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.001 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 41 | HUNTINGTON NATIONAL BANK | 3.0K +— (+0.0%) | 8.6K +631.0 (+8.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.15 +32.6% | 18 qtrs — |
| 42 | UBS GROUP AG | 2.6K +2.2K (+621.3%) | 7.3K +6.4K (+678.3%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD2.79 +2.2% | 45 qtrs — |
| 43 | MAI CAPITAL MANAGEMENT | 2.1K +— (+0.0%) | 5.9K +431.0 (+7.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.14 +33.2% | 4 qtrs — |
| 44 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 1.7K +131.0 (+8.3%) | 4.9K +704.0 (+16.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.20 -54.0% | 14 qtrs — |
| 45 | SBI SECURITIES CO., LTD. | 1.6K +— (+0.0%) | 4.5K +334.0 (+8.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.42 +17.8% | 5 qtrs — |
| 46 | SIMPLEX TRADING, LLC | 1.1K +1.1K (+100.0%) | 3.3K +3.3K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 47 | CAITLIN JOHN, LLC | 1.0K +1.0K (+100.0%) | 2.9K +2.9K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.002 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 48 | MCILRATH & ECK, LLC | 1.0K +— (+0.0%) | 2.9K +210.0 (+8.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.38 -78.7% | 19 qtrs — |
| 49 | JONES FINANCIAL COMPANIES LLLP | 714.00 +— (+0.0%) | 2.0K +314.0 (+18.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.49 +14.5% | 6 qtrs — |
| 50 | TOWER RESEARCH CAPITAL LLC (TRC) | 693.00 +693.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.85 +0.0% | 1 qtrs NEW |
| 51 | FMR LLC | 500.00 +— (+0.0%) | 1.4K +105.0 (+8.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.64 +8.0% | 2 qtrs — |
| 52 | IFP ADVISORS, INC | 500.00 +— (+0.0%) | 1.4K +105.0 (+8.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.54 -80.4% | 19 qtrs — |
| 53 | GOLDEN STATE WEALTH MANAGEMENT, LLC | 303.00 +— (+0.0%) | 864.00 +64.0 (+8.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.42 +17.8% | 5 qtrs — |
| 54 | HOPWOOD FINANCIAL SERVICES, INC. | — -200.0 (-100.0%) | — -528.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 55 | ROYAL BANK OF CANADA | — -3.5K (-100.0%) | — -9.0K (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD— | 51 qtrs SOLD |
| 56 | ALLWORTH FINANCIAL LP | — -300.0 (-100.0%) | — -792.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 57 | CITIGROUP INC | — -4.0 (-100.0%) | — -11.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 58 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | — -1.0K (-100.0%) | — -2.6K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 31 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.03% | 464.5K | 0.60% |
| 2 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 225.6K | 0.20% |
| 3 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.01% | 28.5K | 0.39% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.27M | 0.24% |
| 5 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 224.8K | 0.25% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 143.3K | 0.30% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.00% | 64.3K | 0.08% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 13.8K | 0.25% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 1.8K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.00% | 2.61M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.77
Neutral
Buys
8
Sells
8
Shares acquired
644.3K
Shares disposed
832.1K
Cash buys
—
Cash sales
—
Net activity
-187,727
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | Kidron Miriam | Director / Officer | F-InKind | D | Common Stock | 435,084 | 3.31 | 1.44M | 1,133,138 | D | ↗ |
| 2026-03-30 | KIDRON NADAV | Director / Officer | F-InKind | D | Common Stock | 44,818 | 3.31 | 148.3K | 3,422,243 | D | ↗ |
| 2026-03-17 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 119,558 | 0.00 | — | 1,568,222 | D | ↗ |
| 2026-03-17 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 167,005 | 0.00 | — | 3,422,243 | D | ↗ |
| 2026-03-17 | Hexter Joshua | Officer | A-Award | A | Common Stock | 95,889 | 0.00 | — | 1,160,384 | D | ↗ |
| 2026-03-17 | Gabay Avraham | Officer | A-Award | A | Common Stock | 95,889 | 0.00 | — | 745,145 | D | ↗ |
| 2026-03-12 | KIDRON NADAV | Director / Officer | G-Gift | D | Common Stock | 100,000 | 0.00 | — | 3,255,238 | D | ↗ |
| 2026-01-22 | Kidron Miriam | Director / Officer | M-Exempt | D | Performance Stock Units | 19,000 | 0.00 | — | 0 | D | ↗ |
| 2026-01-22 | KIDRON NADAV | Director / Officer | M-Exempt | D | Performance Stock Units | 109,000 | 0.00 | — | 0 | D | ↗ |
| 2026-01-22 | Hexter Joshua | Officer | M-Exempt | D | Performance Stock Units | 19,000 | 0.00 | — | 0 | D | ↗ |
| 2026-01-22 | Gabay Avraham | Officer | M-Exempt | A | Common Stock | 19,000 | 0.00 | — | 649,256 | D | ↗ |
| 2026-01-14 | Kidron Miriam | Director / Officer | G-Gift | D | Common Stock | 86,166 | 0.00 | — | 1,343,498 | D | ↗ |
| 2025-12-31 | Shapiro Benjamin | Director | A-Award | A | Common Stock | 30,000 | 0.01 | 360.00 | 119,720 | D | ↗ |
| 2025-12-31 | Reznick Yehuda | Director | A-Award | A | Common Stock | 30,000 | 0.01 | 360.00 | 98,930 | D | ↗ |
| 2025-12-31 | Mayer Arie | Director | A-Award | A | Common Stock | 30,000 | 0.01 | 360.00 | 163,109 | D | ↗ |
| 2025-12-31 | Kidron Miriam | Director / Officer | A-Award | A | Performance Stock Units | 19,000 | 0.00 | — | 19,000 | D | ↗ |
| 2025-12-31 | KIDRON NADAV | Director / Officer | A-Award | A | Performance Stock Units | 109,000 | 0.00 | — | 109,000 | D | ↗ |
| 2025-12-31 | Hexter Joshua | Officer | A-Award | A | Performance Stock Units | 19,000 | 0.00 | — | 19,000 | D | ↗ |
| 2025-12-31 | Gabay Avraham | Officer | A-Award | A | Performance Stock Units | 19,000 | 0.00 | — | 19,000 | D | ↗ |
| 2025-12-31 | Aghion Daniel | Director | A-Award | A | Common Stock | 30,000 | 0.01 | 360.00 | 107,191 | D | ↗ |
| 2025-06-05 | Shapiro Benjamin | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 85,070 | D | ↗ |
| 2025-06-05 | Sank Leonard | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 128,021 | D | ↗ |
| 2025-06-05 | Reznick Yehuda | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 60,560 | D | ↗ |
| 2025-06-05 | Mayer Arie | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 126,134 | D | ↗ |
| 2025-06-05 | Aghion Daniel | Director | A-Award | A | Common Stock | 8,371 | 0.00 | — | 77,191 | D | ↗ |
| 2025-02-11 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 74,000 | 0.00 | — | 1,074,666 | D | ↗ |
| 2025-02-11 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 186,000 | 0.00 | — | 2,586,598 | D | ↗ |
| 2025-02-11 | Hexter Joshua | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 751,333 | D | ↗ |
| 2025-02-11 | Gabay Avraham | Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 392,040 | D | ↗ |
| 2025-01-02 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 207,000 | 0.00 | — | 1,000,666 | D | ↗ |
| 2025-01-02 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 433,500 | 0.00 | — | 2,259,598 | D | ↗ |
| 2025-01-02 | Hexter Joshua | Officer | A-Award | A | Common Stock | 194,500 | 0.00 | — | 706,333 | D | ↗ |
| 2025-01-02 | Gabay Avraham | Officer | A-Award | A | Common Stock | 188,000 | 0.00 | — | 358,040 | D | ↗ |
| 2024-11-07 | Kidron Miriam | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 793,666 | D | ↗ |
| 2024-11-07 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 1,826,098 | D | ↗ |
| 2024-11-07 | Hexter Joshua | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 511,833 | D | ↗ |
| 2024-11-07 | Gabay Avraham | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 170,040 | D | ↗ |
| 2024-06-21 | Gabay Avraham | Officer | A-Award | A | Common Stock | 140,040 | 0.00 | — | 0 | — | ↗ |
| 2024-06-18 | Gabay Avraham | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-06 | Reznick Yehuda | Director | A-Award | A | Common Stock | 760 | 0.00 | — | 30,560 | — | ↗ |
| 2024-04-17 | Reznick Yehuda | Director | A-Award | A | Common Stock | 29,800 | 0.00 | — | 29,800 | — | ↗ |
| 2024-04-01 | Reznick Yehuda | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-30 | Aghion Daniel | Director | A-Award | A | Common Stock | 3,750 | 0.00 | — | 38,820 | — | ↗ |
| 2024-01-04 | Silberman David | Officer | A-Award | A | Common Stock | 136,500 | 0.00 | — | 366,500 | — | ↗ |
| 2024-01-04 | Shapiro Benjamin | Director | A-Award | A | Common Stock | 5,070 | 0.00 | — | 55,070 | — | ↗ |
| 2024-01-04 | Sank Leonard | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 88,696 | — | ↗ |
| 2024-01-04 | Rozov Yadin | Director | A-Award | A | Common Stock | 8,820 | 0.00 | — | 155,320 | — | ↗ |
| 2024-01-04 | Mayer Arie | Director | A-Award | A | Common Stock | 9,325 | 0.00 | — | 96,134 | — | ↗ |
| 2024-01-04 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 295,500 | 0.00 | — | 763,666 | — | ↗ |
| 2024-01-04 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 329,000 | 0.00 | — | 1,781,098 | — | ↗ |
| 2024-01-04 | Hexter Joshua | Officer | A-Award | A | Common Stock | 180,500 | 0.00 | — | 481,833 | — | ↗ |
| 2024-01-04 | Aghion Daniel | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2024-01-01 | Aghion Daniel | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-26 | Silberman David | Officer | A-Award | A | Common Stock | 24,500 | 0.00 | — | 230,000 | — | ↗ |
| 2023-05-26 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 53,500 | 0.00 | — | 468,166 | — | ↗ |
| 2023-05-26 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 120,000 | 0.00 | — | 1,452,098 | — | ↗ |
| 2023-05-26 | Hexter Joshua | Officer | A-Award | A | Common Stock | 27,000 | 0.00 | — | 301,333 | — | ↗ |
| 2023-05-26 | Derovan Netanel | Officer | A-Award | A | Common Stock | 20,500 | 0.00 | — | 149,500 | — | ↗ |
| 2023-05-01 | Shapiro Benjamin | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-04-17 | Silberman David | Officer | A-Award | A | Common Stock | 97,500 | 0.00 | — | 205,500 | — | ↗ |
| 2023-04-17 | Sank Leonard | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 58,696 | — | ↗ |
| 2023-04-17 | Rozov Yadin | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 116,500 | — | ↗ |
| 2023-04-17 | Mayer Arie | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 56,809 | — | ↗ |
| 2023-04-17 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 213,000 | 0.00 | — | 414,666 | — | ↗ |
| 2023-04-17 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 279,000 | 0.00 | — | 1,332,098 | — | ↗ |
| 2023-04-17 | Hexter Joshua | Officer | A-Award | A | Common Stock | 108,000 | 0.00 | — | 274,333 | — | ↗ |
| 2023-04-17 | Derovan Netanel | Officer | A-Award | A | Common Stock | 81,000 | 0.00 | — | 129,000 | — | ↗ |
| 2023-04-04 | Mayer Arie | Director | P-Purchase | A | Common Stock | 3,800 | 2.21 | 8.4K | 26,809 | — | ↗ |
| 2023-04-03 | Mayer Arie | Director | P-Purchase | A | Common Stock | 5,009 | 2.22 | 11.1K | 23,009 | — | ↗ |
| 2023-03-16 | KIDRON NADAV | Director / Officer | P-Purchase | A | Common Stock | 26,000 | 2.04 | 53.0K | 126,000 | — | ↗ |
| 2023-03-14 | Rozov Yadin | Director | P-Purchase | A | Common Stock | 50,000 | 2.05 | 102.5K | 86,500 | — | ↗ |
| 2023-03-14 | Kidron Miriam | Director / Officer | S-Sale | D | Common Stock | 100,000 | 2.01 | 201.0K | 201,666 | — | ↗ |
| 2023-03-14 | KIDRON NADAV | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 2.01 | 201.0K | 100,000 | — | ↗ |
| 2023-03-13 | Rozov Yadin | Director | P-Purchase | A | Common Stock | 20,000 | 1.96 | 39.1K | 36,500 | — | ↗ |
| 2023-01-03 | Rabinowitz Michael | Officer | S-Sale | D | Common Stock | 11,900 | 12.49 | 148.7K | 126,143 | — | ↗ |
| 2022-10-27 | KIDRON NADAV | Officer | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 1,053,098 | — | ↗ |
| 2022-08-08 | Sank Leonard | Director | M-Exempt | A | Common Stock | 20,000 | 4.08 | 81.6K | 38,000 | — | ↗ |
| 2022-07-28 | Silberman David | Officer | A-Award | A | Common Stock | 39,000 | 0.00 | — | 108,000 | — | ↗ |
| 2022-07-28 | Sank Leonard | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-07-28 | Rozov Yadin | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 16,500 | — | ↗ |
| 2022-07-28 | Rabinowitz Michael | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 139,468 | — | ↗ |
| 2022-07-28 | Mayer Arie | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-07-28 | Kidron Miriam | Officer | A-Award | A | Common Stock | 84,000 | 0.00 | — | 301,666 | — | ↗ |
| 2022-07-28 | KIDRON NADAV | Officer | A-Award | A | Common Stock | 126,000 | 0.00 | — | 1,090,729 | — | ↗ |
| 2022-07-28 | Hexter Joshua | Officer | A-Award | A | Common Stock | 42,000 | 0.00 | — | 166,333 | — | ↗ |
| 2022-07-28 | Derovan Netanel | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 48,000 | — | ↗ |
| 2022-05-02 | Rozov Yadin | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-04-01 | Rozov Yadin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-21 | RAKIN KEVIN | Director | S-Sale | D | Common Stock | 10,000 | 9.41 | 94.1K | 46,661 | — | ↗ |
| 2022-02-17 | RAKIN KEVIN | Director | M-Exempt | A | Common Stock | 6,667 | 4.80 | 32.0K | 59,671 | — | ↗ |
| 2022-02-11 | RAKIN KEVIN | Director | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 47,004 | — | ↗ |
| 2022-01-09 | Derovan Netanel | Officer | A-Award | A | Common Stock | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-01-03 | Silberman David | Officer | A-Award | A | Common Stock | 19,000 | 0.00 | — | 69,000 | — | ↗ |
| 2022-01-03 | Sank Leonard | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2022-01-03 | Rabinowitz Michael | Officer | A-Award | A | Stock Option (right to buy) | 32,000 | 13.89 | 444.5K | 32,000 | — | ↗ |
| 2022-01-03 | RAKIN KEVIN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 13.89 | 138.9K | 10,000 | — | ↗ |
| 2022-01-03 | Mayer Arie | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-01-03 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 42,000 | 0.00 | — | 183,666 | — | ↗ |
| 2022-01-03 | KIDRON NADAV | Director / Officer | F-InKind | D | Common Stock | 48,752 | 13.89 | 677.2K | 887,729 | D | ↗ |
| 2022-01-03 | Hexter Joshua | Officer | A-Award | A | Stock Option (right to buy) | 36,000 | 13.89 | 500.0K | 36,000 | — | ↗ |
| 2022-01-03 | Friedman Aviad | Director | G-Gift | D | Common Stock | 6,000 | 0.00 | — | 0 | — | ↗ |
| 2021-12-30 | KIDRON NADAV | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 766,481 | — | ↗ |
| 2021-12-28 | Rabinowitz Michael | Officer | F-InKind | D | Common Stock | 9,532 | 12.98 | 123.7K | 90,468 | — | ↗ |
| 2021-12-28 | KIDRON NADAV | Director / Officer | F-InKind | D | Common Stock | 31,728 | 12.98 | 411.8K | 786,481 | — | ↗ |
| 2021-12-16 | RAKIN KEVIN | Director | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 52,004 | — | ↗ |
| 2021-12-03 | KIDRON NADAV | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 818,209 | — | ↗ |
| 2021-11-01 | Mayer Arie | Director | S-Sale | D | Common Stock | 3,000 | 25.60 | 76.8K | 0 | — | ↗ |
| 2021-09-16 | RAKIN KEVIN | Director | S-Sale | D | Common Stock | 21,100 | 20.99 | 442.8K | 57,004 | — | ↗ |
| 2021-09-01 | Silberman David | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-08-31 | RAKIN KEVIN | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 78,104 | — | ↗ |
| 2021-08-31 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 66,666 | 0.00 | — | 141,666 | — | ↗ |
| 2021-08-31 | KIDRON NADAV | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 838,209 | — | ↗ |
| 2021-08-31 | Hexter Joshua | Officer | A-Award | A | Common Stock | 33,333 | 0.00 | — | 103,333 | — | ↗ |
| 2021-08-31 | Friedman Aviad | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-09 | RAKIN KEVIN | Director | M-Exempt | D | Stock Option (right to buy) | 56,773 | 7.77 | 441.1K | 0 | — | ↗ |
| 2021-08-09 | KIDRON NADAV | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 220,000 | 20.11 | 4.42M | 648,573 | — | ↗ |
| 2021-08-04 | Rabinowitz Michael | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 15.10 | 1.51M | 100,000 | — | ↗ |
| 2021-08-01 | Rabinowitz Michael | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-05 | Silberman David | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-26 | Sank Leonard | Director | J-Other | D | Common Stock | 78,125 | 3.68 | 287.5K | 0 | — | ↗ |
| 2021-02-17 | RAKIN KEVIN | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 11.33 | 170.0K | 15,000 | — | ↗ |
| 2021-02-03 | Kidron Miriam | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 10.40 | 1.04M | 100,000 | — | ↗ |
| 2021-02-03 | KIDRON NADAV | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 150,000 | 10.40 | 1.56M | 150,000 | — | ↗ |
| 2021-02-03 | Hexter Joshua | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 10.40 | 520.0K | 50,000 | — | ↗ |
| 2021-02-03 | Gabay Avraham | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 10.40 | 416.0K | 40,000 | — | ↗ |
| 2020-01-08 | Xiaoming Gao | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 4.80 | 96.0K | 20,000 | — | ↗ |
| 2020-01-08 | Sank Leonard | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 4.80 | 96.0K | 20,000 | — | ↗ |
| 2020-01-08 | RAKIN KEVIN | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 4.80 | 96.0K | 20,000 | — | ↗ |
| 2020-01-08 | Mayer Arie | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 4.80 | 96.0K | 20,000 | — | ↗ |
| 2020-01-08 | Kidron Miriam | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 4.80 | 480.0K | 100,000 | — | ↗ |
| 2020-01-08 | KIDRON NADAV | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 190,000 | 4.80 | 912.0K | 190,000 | — | ↗ |
| 2020-01-08 | Friedman Aviad | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 4.80 | 96.0K | 20,000 | — | ↗ |
| 2019-12-05 | Mayer Arie | Director | — | D | Common Stock | 0 | 0.00 | — | 3,000 | — | ↗ |
| 2019-09-12 | RAKIN KEVIN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 4.17 | 41.7K | 10,000 | — | ↗ |
| 2019-09-12 | Kidron Miriam | Director / Officer | A-Award | A | Stock Option (right to buy) | 104,000 | 3.16 | 328.6K | 104,000 | — | ↗ |
| 2019-09-12 | KIDRON NADAV | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 196,500 | 3.16 | 620.9K | 196,500 | — | ↗ |
| 2019-09-12 | Hexter Joshua | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 3.69 | 369.0K | 100,000 | — | ↗ |
| 2019-09-12 | Gabay Avraham | Officer | A-Award | A | Stock Option (right to buy) | 33,146 | 3.55 | 117.7K | 33,146 | — | ↗ |
| 2019-09-09 | Sank Leonard | Director | P-Purchase | A | Common Stock | 15,000 | 2.90 | 43.5K | 364,999 | — | ↗ |
| 2019-09-08 | Hexter Joshua | Officer | — | D | Common Stock | 0 | 0.00 | — | 70,000 | — | ↗ |
| 2019-07-18 | Sank Leonard | Director | P-Purchase | A | Common Stock | 4,497 | 3.86 | 17.3K | 349,999 | — | ↗ |
| 2019-07-17 | Sank Leonard | Director | P-Purchase | A | Common Stock | 10,020 | 3.74 | 37.5K | 345,502 | — | ↗ |
| 2019-07-16 | Sank Leonard | Director | P-Purchase | A | Common Stock | 20,000 | 3.47 | 69.3K | 315,482 | — | ↗ |
| 2019-07-11 | Sank Leonard | Director | P-Purchase | A | Common Stock | 1,320 | 3.22 | 4.3K | 295,482 | — | ↗ |
| 2019-07-01 | Xiaoming Gao | Director | — | I | Common Stock | 0 | 0.00 | — | 1,155,367 | — | ↗ |
| 2019-06-17 | Gabay Avraham | Officer | D-Return | D | Stock Option (right to buy) | 33,146 | 3.55 | 117.7K | 0 | — | ↗ |
| 2019-06-01 | Gabay Avraham | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-15 | Slager David Mark | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 4.13 | 82.6K | 20,000 | — | ↗ |
| 2019-04-10 | RAKIN KEVIN | Director | D-Return | D | Stock Option (right to buy) | 10,000 | 4.17 | 41.7K | 0 | — | ↗ |
| 2019-02-26 | Kidron Miriam | Director / Officer | D-Return | D | Stock Option (right to buy) | 104,000 | 3.16 | 328.6K | 0 | — | ↗ |
| 2019-02-26 | KIDRON NADAV | Director / Officer / 10% Owner | D-Return | D | Stock Option (right to buy) | 196,500 | 3.16 | 620.9K | 0 | — | ↗ |
| 2019-02-26 | Hasleton Mark Daniel | Officer | A-Award | A | Stock Option (right to buy) | 22,500 | 3.16 | 71.1K | 22,500 | — | ↗ |
| 2019-02-26 | Eisenberg Hilla | Officer | A-Award | A | Stock Option (right to buy) | 37,000 | 3.16 | 116.9K | 37,000 | — | ↗ |
| 2018-11-15 | Hasleton Mark Daniel | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-09 | Friedman Aviad | Director | P-Purchase | A | Common Stock | 2,000 | 4.98 | 10.0K | 12,191 | — | ↗ |
| 2018-07-11 | KIDRON NADAV | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 122 | 5.92 | 722.18 | 958,209 | — | ↗ |
| 2018-07-10 | KIDRON NADAV | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 61 | 5.98 | 364.97 | 958,087 | — | ↗ |
| 2018-05-03 | Hexter Joshua | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 6.70 | 201.0K | 30,000 | — | ↗ |
| 2018-04-08 | Hexter Joshua | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 7.05 | 211.5K | 30,000 | — | ↗ |
| 2018-01-31 | Kidron Miriam | Director / Officer | A-Award | A | Stock Option (right to buy) | 47,000 | 8.14 | 382.6K | 47,000 | — | ↗ |
| 2018-01-31 | KIDRON NADAV | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 97,000 | 8.14 | 789.6K | 97,000 | — | ↗ |
| 2018-01-31 | Eisenberg Hilla | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 8.14 | 122.1K | 15,000 | — | ↗ |
| 2017-10-31 | Slager David Mark | Director | M-Exempt | A | Common Stock | 16,892 | 3.77 | 63.6K | 1,316,328 | — | ↗ |
| 2017-10-23 | Sank Leonard | Director | M-Exempt | D | Warrant (right to buy) | 6,373 | 6.00 | 38.2K | 0 | — | ↗ |
| 2017-08-17 | Slager David Mark | Director | M-Exempt | A | Common Stock | 112,613 | 3.77 | 424.1K | 1,299,436 | — | ↗ |
| 2017-08-15 | Sank Leonard | Director | M-Exempt | A | Common Stock | 11,262 | 6.00 | 67.6K | 282,158 | — | ↗ |
| 2017-08-02 | Li Xiaopeng | Director | P-Purchase | A | COMMON STOCK | 89,636 | 8.50 | 761.9K | 206,350 | — | ↗ |
| 2017-08-02 | Kidron Miriam | Director / Officer | S-Sale | D | Common Stock | 89,636 | 8.50 | 761.9K | 75,000 | — | ↗ |
| 2017-08-01 | Eisenberg Hilla | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2017-06-30 | Zommer Yifat Hen | Officer | A-Award | A | Stock Option (right to buy) | 20,001 | 7.77 | 155.4K | 20,001 | — | ↗ |
| 2017-06-30 | Slager David Mark | Director | A-Award | A | Stock Option (right to buy) | 16,773 | 7.77 | 130.3K | 16,773 | — | ↗ |
| 2017-06-30 | Sank Leonard | Director | A-Award | A | Stock Option (right to buy) | 16,773 | 7.77 | 130.3K | 16,773 | — | ↗ |
| 2017-06-30 | RAKIN KEVIN | Director | A-Award | A | Stock Option (right to buy) | 56,773 | 7.77 | 441.1K | 56,773 | — | ↗ |
| 2017-06-30 | Li Xiaopeng | Director | A-Award | A | Stock Option (right to buy) | 16,773 | 7.77 | 130.3K | 16,773 | — | ↗ |
| 2017-06-30 | Kidron Miriam | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 164,636 | — | ↗ |
| 2017-06-30 | KIDRON NADAV | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 147,000 | 7.77 | 1.14M | 147,000 | — | ↗ |
| 2017-06-30 | Friedman Aviad | Director | A-Award | A | Stock Option (right to buy) | 16,773 | 7.77 | 130.3K | 16,773 | — | ↗ |
| 2017-04-19 | Li Xiaopeng | Director | P-Purchase | A | Common Stock | 52,814 | 6.33 | 334.3K | 116,714 | — | ↗ |
| 2017-04-19 | Kidron Miriam | Director / Officer | S-Sale | D | Common Stock | 52,814 | 6.33 | 334.3K | 89,636 | — | ↗ |
| 2017-03-20 | Law Ronald Edward | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-02-09 | Slager David Mark | Director | A-Award | A | Stock Option (right to buy) | 5,697 | 6.23 | 35.5K | 5,697 | — | ↗ |
| 2017-02-09 | RAKIN KEVIN | Director | A-Award | A | Stock Option (right to buy) | 5,697 | 6.23 | 35.5K | 5,697 | — | ↗ |
| 2017-02-09 | Li Xiaopeng | Director | A-Award | A | Stock Option (right to buy) | 12,253 | 1.00 | 12.3K | 12,253 | — | ↗ |
| 2017-02-09 | Friedman Aviad | Director | A-Award | A | Stock Option (right to buy) | 4,084 | 1.00 | 4.1K | 4,084 | — | ↗ |
| 2016-12-06 | RAKIN KEVIN | Director | A-Award | A | Common Stock | 3,300 | 6.59 | 21.8K | 15,061 | — | ↗ |
| 2016-12-05 | RAKIN KEVIN | Director | A-Award | A | Common Stock | 2,300 | 6.38 | 14.7K | 11,761 | — | ↗ |
| 2016-12-02 | RAKIN KEVIN | Director | A-Award | A | Common Stock | 7,261 | 6.21 | 45.1K | 9,461 | — | ↗ |
| 2016-12-01 | RAKIN KEVIN | Director | A-Award | A | Common Stock | 2,200 | 6.08 | 13.4K | 2,200 | — | ↗ |
| 2016-11-07 | Li Xiaopeng | Director | A-Award | A | Common Stock | 63,900 | 7.42 | 474.1K | 63,900 | — | ↗ |
| 2016-11-01 | Hexter Joshua | Officer | A-Award | A | Common Stock | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2016-08-30 | Slager David Mark | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,186,823 | — | ↗ |
| 2016-08-30 | RAKIN KEVIN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-08-30 | Friedman Aviad | Director | — | I | Common Stock | 0 | 0.00 | — | 9,691 | — | ↗ |
| 2016-05-20 | Sank Leonard | Director | A-Award | A | Common Stock | 3,000 | 8.57 | 25.7K | 270,896 | — | ↗ |
| 2016-05-12 | KIDRON NADAV | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100 | 7.10 | 710.00 | 958,148 | — | ↗ |
| 2016-03-10 | JACOB HAROLD | Director | S-Sale | D | Common Stock | 8,500 | 6.45 | 54.8K | 16,396 | — | ↗ |
| 2016-01-13 | Li Xiaopeng | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-12-30 | Kidron Miriam | Director / Officer | S-Sale | D | Common Stock | 24,000 | 8.61 | 206.7K | 142,450 | — | ↗ |
| 2015-12-29 | Kidron Miriam | Director / Officer | S-Sale | D | Common Stock | 15,000 | 9.08 | 136.2K | 166,450 | — | ↗ |
| 2015-12-28 | Kidron Miriam | Director / Officer | S-Sale | D | Common Stock | 11,000 | 9.27 | 101.9K | 181,450 | — | ↗ |
Executive team
Top executives
EBIT / Employee
57.9K
Shares Outstanding
40.93M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Nadav Kidron President, Chief Executive Officer and Chairman | 540.1K | 270.8K | 1.22M | — | — | 62.0K | 2.10M | 58.39% | ↗ |
| 2 | 2024 | Dr. Miriam Kidron Chief Scientific Officer and director | 408.1K | 155.3K | 951.5K | — | — | 19.6K | 1.53M | 62.01% | ↗ |
| 3 | 2024 | Joshua Hexter Chief Operating & Business Officer | 259.0K | 94.0K | 608.5K | — | — | 69.9K | 1.03M | 59.00% | ↗ |
| 4 | 2023 | Nadav Kidron President, Chief Executive Officer and Chairman | 463.0K | 242.6K | 904.9K | — | — | 48.7K | 1.66M | 54.54% | ↗ |
| 5 | 2023 | Dr. Miriam Kidron Chief Scientific Officer and director | 347.4K | 139.1K | 605.5K | — | — | 17.4K | 1.11M | 54.58% | ↗ |
| 6 | 2023 | Joshua Hexter Chief Operating & Business Officer | 272.1K | 84.6K | 306.7K | — | — | 65.0K | 728.4K | 42.11% | ↗ |
| 7 | 2023 | David Silberman Chief Financial Officer | 156.1K | 62.0K | 277.2K | — | — | 41.4K | 536.7K | 51.64% | ↗ |
| 8 | 2022 | Nadav Kidron President, Chief Executive Officer and Chairman | 491.1K | 275.2K | 4.85M | 875.2K | — | 344.7K | 6.83M | 83.74% | ↗ |
| 9 | 2022 | Dr. Miriam Kidron Chief Scientific Officer and director | 378.6K | 140.2K | 1.94M | 588.9K | — | 23.9K | 3.07M | 82.32% | ↗ |
| 10 | 2022 | David Silberman Chief Financial Officer | 155.1K | 49.7K | 759.4K | 261.8K | — | 43.2K | 1.27M | 80.46% | ↗ |
| 11 | 2021 | Nadav Kidron President, Chief Executive Officer and director | 466.0K | 300.0K | 2.00M | 876.7K | — | 382.2K | 4.02M | 71.44% | ↗ |
| 12 | 2021 | Nadav Kidron President, Chief Executive Officer and Chairman | 466.0K | 300.0K | 2.00M | 876.7K | — | 382.2K | 4.02M | 71.44% | ↗ |
| 13 | 2021 | Miriam Kidron Chief Scientific Officer and director | 319.9K | 86.0K | 1.33M | 584.5K | — | 14.2K | 2.33M | 82.01% | ↗ |
| 14 | 2021 | Dr. Miriam Kidron Chief Scientific Officer and director | 319.9K | 86.0K | 1.33M | 584.5K | — | 14.2K | 2.33M | 82.01% | ↗ |
| 15 | 2021 | Michael Rabinowitz Chief Commercial Officer | 30.0K | — | 986.4K | 860.4K | — | — | 1.88M | 98.40% | ↗ |
| 16 | 2021 | Joshua Hexter Chief Operating & Business Officer | 206.2K | 60.0K | 665.2K | 292.2K | — | 60.7K | 1.28M | 74.54% | ↗ |
| 17 | 2021 | David Silberman Chief Financial Officer | 27.8K | — | — | — | — | 4.4K | 32.1K | 0.00% | ↗ |
| 18 | 2020 | Nadav Kidron President, Chief Executive Officer and director | 439.1K | 220.6K | — | 569.1K | — | 539.1K | 1.77M | 32.19% | ↗ |
| 19 | 2020 | Nadav Kidron President and CEO and director | 439.1K | 220.6K | — | 569.1K | — | 539.1K | 1.77M | 32.19% | ↗ |
| 20 | 2020 | Miriam Kidron Chief Scientific Officer and director | 305.8K | 70.0K | — | 299.5K | — | 13.4K | 688.7K | 43.49% | ↗ |
| 21 | 2020 | Joshua Hexter Chief Operating & Business Officer | 190.8K | 12.2K | — | 351.1K | — | 54.7K | 608.8K | 57.67% | ↗ |
| 22 | 2020 | Avraham Gabay Chief Financial Officer | 130.6K | 15.6K | — | — | — | 44.9K | 191.4K | 0.00% | ↗ |
| 23 | 2019 | Nadav Kidron President and Chief Executive Officer and director | 419.5K | 225.0K | — | 398.9K | — | 507.8K | 1.55M | 25.72% | ↗ |
| 24 | 2019 | Nadav Kidron President, Chief Executive Officer and director | 419.5K | 225.0K | — | 398.9K | — | 507.8K | 1.55M | 25.72% | ↗ |
| 25 | 2019 | Nadav Kidron President and CEO and director | 419.5K | 225.0K | — | 398.9K | — | 507.8K | 1.55M | 25.72% | ↗ |
| 26 | 2019 | Miriam Kidron Chief Scientific Officer and director | 267.4K | 123.1K | — | 211.1K | — | 14.5K | 616.2K | 34.26% | ↗ |
| 27 | 2019 | Hilla Eisenberg Chief Financial Officer | 80.1K | 23.9K | — | 75.1K | — | 11.7K | 190.8K | 39.37% | ↗ |
| 28 | 2019 | Mark Hasleton VP Business Development | 114.1K | — | — | 45.7K | — | 18.9K | 178.7K | 25.55% | ↗ |
| 29 | 2019 | Avraham Gabay Chief Financial Officer | 32.1K | — | — | 73.9K | — | 9.4K | 115.5K | 64.01% | ↗ |
| 30 | 2019 | Joshua Hexter Chief Operating & Business Officer | 52.8K | — | — | — | — | 9.0K | 61.9K | 0.00% | ↗ |
| 31 | 2018 | Nadav Kidron President and CEO and director | 436.3K | 148.8K | — | 522.6K | — | 442.3K | 1.55M | 33.71% | ↗ |
| 32 | 2018 | Nadav Kidron President and Chief Executive Officer and director | 436.3K | 148.8K | — | 522.6K | — | 442.3K | 1.55M | 33.71% | ↗ |
| 33 | 2018 | Miriam Kidron Chief Scientific Officer and director | 273.6K | 46.6K | — | 253.2K | — | 13.6K | 587.1K | 43.13% | ↗ |
| 34 | 2018 | Joshua Hexter Chief Operating Officer and VP Business Development | 161.0K | 26.9K | — | 269.2K | — | 50.5K | 507.6K | 53.03% | ↗ |
| 35 | 2018 | Joshua Hexter Chief Operating & Business Officer | 161.0K | 26.9K | — | 269.2K | — | 50.5K | 507.6K | 53.03% | ↗ |
| 36 | 2018 | Hilla Eisenberg Chief Financial Officer | 140.5K | 10.0K | — | 80.8K | — | 26.1K | 257.4K | 31.39% | ↗ |
| 37 | 2017 | Miriam Kidron Chief Scientific Officer and director | 254.8K | 50.0K | 581.9K | 359.2K | — | 12.8K | 1.26M | 74.77% | ↗ |
| 38 | 2017 | Nadav Kidron President and Chief Executive Officer and director | 399.8K | 123.0K | — | 585.2K | — | 45.6K | 1.15M | 50.73% | ↗ |
| 39 | 2017 | Joshua Hexter Chief Operating Officer and VP Business Development | 148.5K | 33.0K | 463.4K | — | — | 46.4K | 691.3K | 67.03% | ↗ |
| 40 | 2017 | Hilla Eisenberg Chief Financial Officer | 87.0K | — | — | 113.0K | — | 16.1K | 200.0K | 56.48% | ↗ |
| 41 | 2016 | Nadav Kidron President and Chief Executive Officer and director | 273.1K | 195.7K | — | — | — | 17.4K | 486.2K | 0.00% | ↗ |
| 42 | 2016 | Nadav Kidron President and CEO and director | 273.1K | 195.7K | — | — | — | 17.4K | 486.2K | 0.00% | ↗ |
| 43 | 2016 | Miriam Kidron Chief Scientific Officer and director | 203.4K | 136.6K | — | — | — | 13.2K | 353.2K | 0.00% | ↗ |
| 44 | 2016 | Joshua Hexter Chief Operating Officer and VP Business Development | 132.3K | 87.0K | — | — | — | 42.0K | 261.3K | 0.00% | ↗ |
| 45 | 2016 | Yifat Zommer Chief Financial Officer, Treasurer and Secretary | 65.2K | 75.6K | — | — | — | 36.4K | 177.3K | 0.00% | ↗ |
| 46 | 2015 | Nadav Kidron President and Chief Executive Officer and director | 254.3K | 63.0K | 431.6K | — | — | 16.2K | 765.2K | 56.41% | ↗ |
| 47 | 2015 | Nadav Kidron President and CEO and director | 254.3K | 63.0K | 431.6K | — | — | 16.2K | 765.2K | 56.41% | ↗ |
| 48 | 2015 | Miriam Kidron Chief Medical and Technology Officer and director | 188.5K | 50.4K | 431.6K | — | — | 13.6K | 684.1K | 63.09% | ↗ |
| 49 | 2015 | Miriam Kidron Chief Scientific Officer and director | 188.5K | 50.4K | 431.6K | — | — | 13.6K | 684.1K | 63.09% | ↗ |
| 50 | 2015 | Yifat Zommer Chief Financial Officer, Treasurer and Secretary | 101.1K | 26.4K | 212.3K | — | — | 34.9K | 374.7K | 56.66% | ↗ |
| 51 | 2015 | Joshua Hexter Chief Operating Officer and VP Business Development | 124.1K | 32.4K | — | — | — | 39.5K | 196.0K | 0.00% | ↗ |
| 52 | 2014 | Nadav Kidron President and CEO and director | 261.3K | 120.0K | — | 390.7K | — | 31.8K | 803.8K | 48.61% | ↗ |
| 53 | 2014 | Miriam Kidron Chief Scientific Officer and director | 206.3K | 65.0K | — | 390.7K | — | 14.7K | 676.7K | 57.73% | ↗ |
| 54 | 2014 | Miriam Kidron Chief Medical and Technology Officer and director | 206.3K | 65.0K | — | 390.7K | — | 14.7K | 676.7K | 57.73% | ↗ |
| 55 | 2014 | Joshua Hexter Chief Operating Officer and VP Business Development | 134.7K | 25.0K | — | — | — | 42.9K | 202.6K | 0.00% | ↗ |
| 56 | 2014 | Yifat Zommer Chief Financial Officer, Treasurer and Secretary | 109.7K | 50.0K | — | — | — | 39.8K | 199.5K | 0.00% | ↗ |
| 57 | 2013 | Joshua Hexter Chief Operating Officer and VP Business Development | 48.4K | — | — | 519.8K | — | 10.0K | 578.2K | 89.89% | ↗ |
| 58 | 2013 | Nadav Kidron President and CEO | 199.7K | 60.0K | — | 104.3K | — | 12.0K | 375.9K | 27.73% | ↗ |
| 59 | 2013 | Miriam Kidron Chief Medical and Technology Officer | 168.4K | 20.0K | — | 104.3K | — | 12.1K | 304.7K | 34.21% | ↗ |
| 60 | 2013 | Nadav Kidron President and CEO and director | 182.5K | 60.0K | — | — | — | 29.2K | 271.7K | 0.00% | ↗ |
| 61 | 2013 | Yifat Zommer CFO, Treasurer and Secretary | 83.4K | 15.0K | — | 93.4K | — | 29.1K | 220.8K | 42.27% | ↗ |
| 62 | 2013 | Miriam Kidron Chief Medical and Technology Officer and director | 168.4K | 20.0K | — | — | — | 12.1K | 200.5K | 0.00% | ↗ |
| 63 | 2013 | Joshua Hexter COO and VP Business Development | 48.4K | — | — | 109.1K | — | 10.0K | 167.5K | 65.11% | ↗ |
| 64 | 2013 | Yifat Zommer Chief Financial Officer, Treasurer and Secretary | 83.4K | 15.0K | — | — | — | 29.1K | 127.5K | 0.00% | ↗ |
| 65 | 2012 | Nadav Kidron President and CEO and director | 159.1K | — | — | 186.8K | — | 18.0K | 363.9K | 51.33% | ↗ |
| 66 | 2012 | Miriam Kidron Chief Medical and Technology Officer and director | 159.1K | — | — | 186.8K | — | 13.2K | 359.1K | 52.01% | ↗ |
| 67 | 2012 | Nadav Kidron President and CEO | 159.1K | — | — | 88.9K | — | 18.0K | 266.1K | 33.42% | ↗ |
| 68 | 2012 | Miriam Kidron Chief Medical and Technology Officer | 159.1K | — | — | 88.9K | — | 13.2K | 261.3K | 34.04% | ↗ |
| 69 | 2012 | Yifat Zommer Chief Financial Officer, Treasurer and Secretary | 58.7K | — | — | 136.2K | — | 29.7K | 224.6K | 60.65% | ↗ |
| 70 | 2012 | Yifat Zommer CFO, Treasurer and Secretary | 58.7K | — | — | 32.9K | — | 29.7K | 121.3K | 27.13% | ↗ |
| 71 | 2011 | Nadav Kidron President and CEO and director | 171.2K | — | — | — | — | 21.0K | 199.4K | 0.00% | ↗ |
| 72 | 2011 | Miriam Kidron Chief Medical and Technology Officer and director | 172.2K | — | — | — | — | 13.6K | 185.8K | 0.00% | ↗ |
| 73 | 2011 | Yifat Zommer CFO, Treasurer and Secretary | 85.7K | — | — | — | — | 32.0K | 117.7K | 0.00% | ↗ |
| 74 | 2010 | Nadav Kidron President and CEO and director | 159.9K | — | — | 423.4K | — | 10.8K | 594.1K | 71.27% | ↗ |
| 75 | 2010 | Miriam Kidron Chief Medical and Technology Officer and director | 160.1K | — | — | 423.4K | — | 7.7K | 591.2K | 71.61% | ↗ |
| 76 | 2010 | Yifat Zommer CFO, Treasurer and Secretary | 76.9K | — | — | — | — | 27.0K | 103.9K | 0.00% | ↗ |
| 77 | 2009 | Nadav Kidron President and CEO and director | 155.4K | — | — | 153.9K | — | 15.5K | 324.7K | 47.39% | ↗ |
| 78 | 2009 | Miriam Kidron Chief Medical and Technology Officer and director | 155.0K | — | — | 153.9K | — | 11.5K | 320.4K | 48.02% | ↗ |
| 79 | 2009 | Chaime Orlev CFO and Secretary | 59.3K | — | — | — | — | 25.5K | 84.8K | 0.00% | ↗ |
| 80 | 2009 | Yifat Zommer CFO, Treasurer and Secretary | 20.5K | — | — | 19.9K | — | 11.2K | 51.7K | 38.61% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nadav Kidron | President, Chief Executive Officer & Executive Chairman | 1M | male |
| Miriam Kidron | Chief Scientific Officer & Director | 760.4K | — |
| Joshua Hexter | Chief Operating & Business Officer | 583.3K | male |
| Avraham Gabay | Chief Financial Officer, Treasurer & Secretary | 303.1K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-01-10 | 2025-02-26 | Brad Knott | NC13 | — | Sale | $15,001 - $50,000 | ↗ |
| 2022-01-14 | 2022-01-14 | Andrew Garbarino | NY02 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-10-01 | 2021-11-03 | Andrew Garbarino | NY02 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2021-04-23 | 2021-05-24 | Andrew Garbarino | NY02 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORMP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
